1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
2. Adam Z, Pour L, Svobodník A, Scudla V, Salajka F, Vytrasová M, Bacovský J, Schützová M, Koza V, Sumná E, Franková H, Lehanka F, Gumulec J, Stavarová Y, Cahová S, Vránová M, Dostálová V, Kessler P, Walterová L, Meluzínová I, Seifertová N, Sláma O, Büchler T, Krejcí M, Bencíková V, Nykodýmová V, Dusek L, Hájek R, Czech Myeloma Group (2002) Quality of life and tolerance of maintenance treatment in patients with multiple myeloma. [Czech]. Vnitr Lek 48:216–229
3. Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32–75
4. Bladé J, Cibeira MT, Fernández de Larrea C, Rosiñol L (2010) Multiple myeloma. Ann Oncol: Official Journal of the European Society for Medical Oncology/ESMO 21(Suppl 7):vii313–vii319
5. Cancer Research UK (2007) http://www.cancerresearchuk.org/ . Accessed 20 Dec 2010